Detection of testosterone microdosing in healthy females.
antidoping
athlete
female
reticulocyte
testosterone
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
08
11
2021
received:
25
08
2021
accepted:
09
11
2021
pubmed:
24
11
2021
medline:
12
4
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
The ready detectability of synthetic androgens by mass spectrometry (MS)-based antidoping tests has reoriented androgen doping to using testosterone (T), which must be distinguished from its endogenous counterpart making detection of exogenous T harder. We investigated urine and serum steroid and hematological profiling individually and combined to determine the optimal detection model for T administration in women. Twelve healthy females provided six paired blood and urine samples over 2 weeks prior to treatment consisting of 12.5-mg T in a topical transdermal gel applied daily for 7 days. Paired blood and urine samples were then obtained at the end of treatment and Days 1, 2, 4, 7, and 14 days later. Compliance with treatment and sampling was high, and no adverse effects were reported. T treatment significantly increased serum and urine T, serum dihydrotestosterone (DHT), urine 5α-androstane-3α,17β-diol (5α-diol) epitestosterone (E), and urine T/E ratio with a brief window of detection (2-4 days) as well as total and immature (medium and high fluorescence) reticulocytes that remained elevated over the full 14 posttreatment days. Carbon isotope ratio MS and the OFF score and Abnormal Blood Profile score (ABPS) were not discriminatory. The optimal multivariate model to identify T exposure combined serum T, urine T/E ratio with three hematological variables (% high fluorescence reticulocytes, mean corpuscular hemoglobin, and volume) with the five variables providing 93% correct classification (4% false positive, 10% false negatives). Hence, combining select serum and urine steroid MS variables with reticulocyte measures can achieve a high but imperfect detection of T administration to healthy females.
Substances chimiques
Androgens
0
Steroids
0
Dihydrotestosterone
08J2K08A3Y
Testosterone
3XMK78S47O
Epitestosterone
481-30-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-666Subventions
Organisme : Partnership for Clean Competition
Informations de copyright
© 2021 State of New South Wales. Drug Testing and Analysis © 2021 John Wiley & Sons Ltd.
Références
WADA. Anti-doping testing figures-laboratory report. Montreal: WADA; 2019.
Handelsman DJ. Commentary: androgens and “anabolic steroids”: the one-headed Janus. Endocrinology. 2011;152(5):1752-1754.
Handelsman DJ. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Performance Enhancing Hormone Doping in Sport. South Dartmouth (MA): Endotext; 2020.
Schänzer W, Delahaut P, Geyer H, Machnik M, Horning S. Long-term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography-high-resolution mass spectrometry. J Chromatogr B Biomed Appl. 1996;687(1):93-108.
Guddat S, Fussholler G, Beuck S, et al. Synthesis, characterization, and detection of new oxandrolone metabolites as long-term markers in sports drug testing. Anal Bioanal Chem. 2013;405(25):8285-8294.
Piper T, Schänzer W, Thevis M. Revisiting the metabolism of 19-nortestosterone using isotope ratio and high resolution/high accuracy mass spectrometry. J Steroid Biochem Mol Biol. 2016;162:80-91.
Piper T, Schänzer W, Thevis M. Genotype-dependent metabolism of exogenous testosterone-new biomarkers result in prolonged detectability. Drug Test Anal. 2016;8(11-12):1163-1173.
Piper T, Putz M, Schanzer W, et al. Epiandrosterone sulfate prolongs the detectability of testosterone, 4-androstenedione, and dihydrotestosterone misuse by means of carbon isotope ratio mass spectrometry. Drug Test Anal. 2017;9(11-12):1695-1703.
Albertsdóttir AD, van Gansbeke W, Coppieters G, Balgimbekova K, van Eenoo P, Polet M. Searching for new long-term urinary metabolites of metenolone and drostanolone using gas chromatography-mass spectrometry with a focus on non-hydrolysed sulfates. Drug Test Anal. 2020;12(8):1041-1053.
Kazlauskas R. Designer steroids. Handb Exp Pharmacol. 2010;195(195):155-185.
Ayotte C. Detecting the administration of endogenous anabolic androgenic steroids. Handb Exp Pharmacol. 2010;195:77-98.
Tretzel L, Thomas A, Geyer H, et al. Use of dried blood spots in doping control analysis of anabolic steroid esters. J Pharm Biomed Anal. 2014;96:21-30.
Forsdahl G, Erceg D, Geisendorfer T, et al. Detection of testosterone esters in blood. Drug Test Anal. 2015;7(11-12):983-989.
Piper T, Emery C, Saugy M. Recent developments in the use of isotope ratio mass spectrometry in sports drug testing. Anal Bioanal Chem. 2011;401(2):433-447.
Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, Rane A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab. 2008;93(7):2500-2506.
Jakobsson J, Ekstrom L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006;91(2):687-693.
Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83(3):337-346.
Martin-Escudero P, Munoz-Guerra J, del Prado N, et al. Impact of UGT2B17 gene deletion on the steroid profile of an athlete. Physiol Rep. 2015;3(12):e12645.
Okano M, Ueda T, Nishitani Y, Kano H, Ikekita A, Kageyama S. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse. Drug Test Anal. 2013;5(3):166-181.
Schulze JJ, Lundmark J, Garle M, Ekstrom L, Sottas PE, Rane A. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids. 2009;74(3):365-368.
Strahm E, Mullen JE, Garevik N, et al. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism. Drug Test Anal. 2015;7(11-12):1063-1070.
Handelsman DJ, Bermon S. Detection of testosterone doping in female athletes. Drug Test Anal. 2019;11(10):1566-1571.
Elings Knutsson J, Andersson A, Baekken LV, Pohanka A, Ekstrom L, Hirschberg AL. Disposition of urinary and serum steroid metabolites in response to testosterone administration in healthy women. J Clin Endocrinol Metab. 2021;106(3):697-707.
Salamin O, Nicoli R, Langer T, et al. Longitudinal evaluation of multiple biomarkers for the detection of testosterone gel administration in women with normal menstrual cycle. Drug Test Anal. 2021.
Börjesson A, Lehtihet M, Andersson A, et al. Studies of Athlete Biological Passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents. Drug Test Anal. 2020;12(4):514-523.
Mullen JE, Thörngren JO, Schulze JJ, et al. Urinary steroid profile in females-the impact of menstrual cycle and emergency contraceptives. Drug Test Anal. 2017;9(7):1034-1042.
Schulze JJ, Mullen JE, Berglund Lindgren E, Ericsson M, Ekström L, Hirschberg AL. The impact of genetics and hormonal contraceptives on the steroid profile in female athletes. Front Endocrinol. 2014;5:50.
Schulze J, Suominen T, Bergström H, Ericsson M, Björkhem Bergman L, Ekström L. Urinary steroid profile in relation to the menstrual cycle. Drug Test Anal. 2021;13(3):550-557.
Salamin O, Ponzetto F, Cauderay M, et al. Development and validation of an UHPLC-MS/MS method for extended serum steroid profiling in female populations. Bioanalysis. 2020;12(11):753-768.
Mullen J, Borjesson A, Hopcraft O, et al. Sensitivity of doping biomarkers after administration of a single dose testosterone gel. Drug Test Anal. 2018;10(5):839-848.
Kaabia Z, Dervilly-Pinel G, Hanganu F, et al. Ultra high performance liquid chromatography/tandem mass spectrometry based identification of steroid esters in serum and plasma: an efficient strategy to detect natural steroids abuse in breeding and racing animals. J Chromatogr A. 2013;1284:126-140.
de la Torre X, Iannone M, Botrè F. Improving the detection of anabolic steroid esters in human serum by LC-MS. J Pharm Biomed Anal. 2021;194:113807.
Salamin O, Nicoli R, Xu C, et al. Steroid profiling by UHPLC-MS/MS in dried blood spots collected from healthy women with and without testosterone gel administration. J Pharm Biomed Anal. 2021;204:114280.
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.
Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.
Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl 4):S3-S5.
Bermon S, Vilain E, Fenichel P, Ritzen M. Women with hyperandrogenism in elite sports: scientific and ethical rationales for regulating. J Clin Endocrinol Metab. 2015;100(3):828-830.
Huang G, Basaria S, Travison TG, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014;21(6):612-623.
Hirschberg AL, Elings Knutsson J, Helge T, et al. Effects of moderately increased testosterone concentration on physical performance in young women: a double blind, randomised, placebo controlled study. Br J Sports Med. 2019;54(10):599-604.
Mullen JE, Gårevik N, Schulze JJ, Rane A, Björkhem Bergman L, Ekström L. Perturbation of the hematopoietic profile by anabolic androgenic steroids. J Hormones. 2014;2014:1-7.
Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med. 2017;177(4):480-490.
Hawkins WW, Speck E, Leonard VG. Variation of the hemoglobin level with age and sex. Blood. 1954;9(10):999-1007.
Handelsman DJ, Hirschberg AL, Bermon S. Circulating testosterone as the hormonal basis of sex differences in athletic performance. Endocr Rev. 2018;39(5):803-829.
Karunasena N, Han TS, Mallappa A, et al. Androgens correlate with increased erythropoiesis in women with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2017;86(1):19-25.
Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta. 2009;409(1-2):78-84.
Keski-Rahkonen P, Desai R, Jimenez M, Harwood DT, Handelsman DJ. Measurement of estradiol in human serum by LC-MS/MS using a novel estrogen-specific derivatization reagent. Anal Chem. 2015;87(14):7180-7186.
Hsu B, Cumming RG, Hirani V, et al. Temporal trend in androgen status and androgen-sensitive outcomes in older men. J Clin Endocrinol Metab. 2016;101(4):1836-1846.
WADA. International Standard for Laboratories (ISL). 2016.
Goebel C, Howe CJ, Ho KK, Nelson A, Kazlauskas R, Trout GJ. Screening for testosterone abuse in male athletes using the measurement of urinary LH, a revision of the paradigm. Drug Test Anal. 2009;1(11-12):511-517.
WADA. Technical document for endogenous anabolic androgenic steroids (TD2018EAAS). 2018.
Singh GK, Jimenez M, Newman R, Handelsman DJ. Immunoreactive LH in long-term frozen human urine samples. Drug Test Anal. 2013;6(4):336-341.
Nair VS, Doman CE, Morrison MS, et al. Evaluation of epiandrosterone as a long-term marker of testosterone use. Drug Test Anal. 2020;12(11-12):1554-1560.
WADA. Technical document for the detection of synthetic forms of prohibited substances by GC/C/IRMS (TD2021IRMS). 2021.
Cawley A, Collins M, Kazlauskas R, et al. Stable isotope ratio profiling of testosterone preparations. Drug Test Anal. 2010;2(11-12):557-567.
Brooker L, Cawley A, Drury J, Edey C, Hasick N, Goebel C. Stable carbon isotope ratio profiling of illicit testosterone preparations-domestic and international seizures. Drug Test Anal. 2014;6(10):996-1001.
Pekelharing J, Hauss O, De Jonge R, et al. Haematology reference intervals for established and novel parameters in healthy adults. Sysmex J Int. 2010;20(1):1-9.
Schutz F, Zollinger A. ABPS: an R package for calculating the abnormal blood profile score. Front Physiol. 2018;9:1638.
Sottas PE, Robinson N, Giraud S, et al. Statistical classificiation of abnormal blood profiles inathletes. Int J Biostat. 2006;2(1):3.
Gore CJ, Parisotto R, Ashenden MJ, et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica. 2003;88(3):333-344.
Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.
Handelsman DJ, Idan A, Grainger J, Goebel C, Turner L, Conway AJ. Detection and effects on serum and urine steroid and LH of repeated GnRH analog (leuprolide) stimulation. J Steroid Biochem Mol Biol. 2014;141:113-120.
Thieme D, Rautenberg C, Grosse J, Schoenfelder M. Significant increase of salivary testosterone levels after single therapeutic transdermal administration of testosterone: suitability as a potential screening parameter in doping control. Drug Test Anal. 2013;5(11-12):819-825.
Badoud F, Boccard J, Schweizer C, Pralong F, Saugy M, Baume N. Profiling of steroid metabolites after transdermal and oral administration of testosterone by ultra-high pressure liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Steroid Biochem Mol Biol. 2013;138:222-235.
Kotronoulas A, Gomez-Gomez A, Fabregat A, et al. Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part I: transdermal administration. Drug Test Anal. 2018;10(5):821-831.
Handelsman DJ. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Androgen Physiology, Pharmacology, Use and Misuse. South Dartmouth (MA): Endotext; 2020.
Wang C, Berman N, Longrstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J Clin Endocrinol Metabol. 2000;85(3):964-969.
Nathorst-Boos J, Jarkander-Rolff M, Carlstrom K, Floter A, von Schoultz B. Percutaneous administration of testosterone gel in postmenopausal women-a pharmacological study. Gynecol Endocrinol. 2005;20(5):243-248.
Nishifuji K, Yoon JS. The stratum corneum: the rampart of the mammalian body. Vet Dermatol. 2013;24(1):60-72.
Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42-48.
Savkovic S, Lim S, Jayadev V, et al. Urine and serum sex steroid profile in testosterone-treated transgender and hypogonadal and healthy control men. J Clin Endocrinol Metab. 2018;103(6):2277-2283.
Piper T, Mareck U, Geyer H, et al. Determination of 13C/12C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. Rapid Commun Mass Spectrom. 2008;22(14):2161-2175.
Dehennin L, Ferry M, Lafarge P, Peres G, Lafarge JP. Oral administration of dehydroepiandrosterone to healthy men: alteration of the urinary androgen profile and consequences for the detection of abuse in sport by gas chromatography-mass spectrometry. Steroids. 1998;63(2):80-87.
Ekblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion. J Appl Physiol. 1972;33(2):175-180.
Nelson M, Popp H, Sharpe K, Ashenden M. Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica. 2003;88(11):1284-1295.
Sottas PE, Robinson N, Saugy M. The Athlete's Biological Passport and indirect markers of blood doping. Handb Exp Pharmacol. 2010;195:305-326.
Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem. 1997;43(7):1262-1279.
Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670-2677.
Lesesve JF, Lacombe F, Marit G, Bernard P, Belloc F, Reiffers J. High fluorescence reticulocytes are an indicator of bone marrow recovery after chemotherapy. Eur J Haematol. 1995;54(1):61-63.
Molina JR, Sanchez-Garcia J, Torres A, et al. Reticulocyte maturation parameters are reliable early predictors of hematopoietic engraftment after allogeneic stem cell transplantation. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpla. 2007;13(2):172-182.
Piva E, Brugnara C, Spolaore F, Plebani M. Clinical utility of reticulocyte parameters. Clin Lab Med. 2015;35(1):133-163.
Solheim SA, Morkeberg J, Dehnes Y, et al. Changes in blood parameters after intramuscular testosterone ester injections-implications for anti-doping. Drug Test Anal. 2020;12(8):1019-1030.
Nair VS, Sharpe K, Husk J, et al. Evaluation of blood parameters by linear discriminant models for the detection of testosterone administration. Drug Test Anal. 2021;13(7):1270-1281.